Reading LIVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LIVN free→Reading LIVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LIVN free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. However, the sector backdrop is a headwind, and risk is moderate. Peer multiples imply a price roughly in line with where it trades (about fair); the read is fair, but weakening. If LIVN cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $79.39. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $79 LIVN trades at 20× p/e, below its 23× p/e peer median. Our $84 fair value sits above the price; high confidence. Analysts: $76–$90. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 6% below a flat-multiple fair value, below our forecast of about 13%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.29x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.09 → $1.09 (-0.1% / 30d). 4 raised, 1 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$146.
How much price usually moves either way.
On a bad day, this stock has moved -$301.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,889.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth falls below the median, it could signal a slowdown in LivaNova's business. This would be a concern for investors.
Confirms:LivaNova reports revenue growth below the sector median of 1% year over year.
Disproves:LivaNova reports revenue growth above the sector median of 1% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LIVN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 6, 2026, LivaNova PLC (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026. The Company will host a business update conference call and webcast today, May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available through the LivaNova website at www.livanova.com/events . A copy of the Company’s p…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$76.00 – $90.00 (median $81.00) · 5 analysts · as of 2026-05-07
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LIVN LivaNova | Above typical Show detailsSector percentile: 82 of 100 | fair | moderate |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 67 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not enough signal yet.
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
LivaNova aims to achieve a revenue growth rate of 7-8% for the full year 2026.
LivaNova aims to maintain adjusted free cash flow within the range of $160 million to $180 million for 2026.
LivaNova has raised its adjusted diluted EPS guidance for 2026 to a range of $4.20 to $4.30.
Why it matters: Hitting this target shows LivaNova can keep growing in 2026.
Confirms:Q2 revenue growth of 7% or more compared to Q2 2025.
Disproves:Q2 revenue growth falls below 7% YoY.
Why it matters: A successful market entry could lead to big revenue growth in the OSA segment.
Confirms:Official announcement of the aura6000 System launch in the U.S. market.
Disproves:Delays or setbacks in the market launch of the aura6000 System.
Why it matters: Keeping this guidance shows trust in steady earnings and growth.
Confirms:Adjusted EPS guidance remains in the range of $4.20 to $4.30.
Disproves:Adjusted EPS guidance is now below $4.20.
Why it matters: Reaching this target shows strong cash flow and good financial health.
Confirms:Adjusted free cash flow reported in the range of $160 million to $180 million.
Disproves:Adjusted free cash flow falls below $160 million.
Why it matters: The Q2 results will show if LivaNova's financial health is improving or not. Investors will look for signs of recovery or continued losses.
Confirms one read:Earnings report shows revenue growth year over year of at least 5%.
Confirms the other:Earnings report shows revenue decline year over year of more than -5%.